In the year to March 2002, spending on direct-to-consumer (DTC) advertising for a single product in the US was highest for AstraZeneca's esomeprazole [`Nexium'] at $US177 million

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.398, 2003-01, pp. : 16-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An IV formulation of esomeprazole [Nexium] has been launched in the UK by AstraZeneca

By  

Inpharma, Vol. 1, Iss. 1431, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

DTC advertising planned for `NuvaRing', changes suggested by AstraZeneca

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

AstraZeneca's rosuvastatin up against Pfizer's atorvastatin in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 426, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

US group calls for rosuvastatin removal, AstraZeneca responds

By  

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Spending on DTC advertising on the rise

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 351, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite